pharmaphorum1d
Zytiga is powerhouse for J&J - but for how long?
But it remains to be seen how long this can continue because of dwindling sales of its inflammatory disease drug Remicade and a looming threat to Zytiga. Zytiga (abiraterone), approved since 2011 ...
pharmaphorum2d
NICE says no to early use of prostate cancer drug
Janssen's prostate cancer drug Zytiga should not be used earlier in patients, because it would not be cost effective, says NICE. Draft guidance from the cost effectiveness watchdog says Zytiga ...
Hosted on MSN3mon
Medicare Pays Wildly Different Prices for the Same Drug
The cost of prescription drugs in the U.S. isn’t like the tabs for other products. The price for a single medicine can range by thousands of dollars depending on the drug plan. It is a symptom ...
Targeted Oncology3d
mHSPC Regimens Are Distinguished by Drug Interactions and Disease Volume
In a live event, Ganesh V. Raj, MD, PhD, discussed the drug-drug interactions and outcomes by disease volumes across ARPI ...
The Globe and Mail24d
Metastatic Prostate Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
The large food effect of Zytiga is also avoided ... with only mild-to-moderate side effects reported. Currently, the drug is in Phase II stage of its development for the treatment of prostate ...